Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Adicionar filtros








Intervalo de ano
1.
Chinese Journal of Integrated Traditional and Western Medicine ; (12): 902-905, 2012.
Artigo em Chinês | WPRIM | ID: wpr-288491

RESUMO

<p><b>OBJECTIVE</b>To explore the efficacy of concurrent chemoradiotherapy combined with Kanglaite Injection (KI) for locally advanced pancreatic carcinoma patients.</p><p><b>METHODS</b>Totally 50 patients unsuitable for surgery were randomly assigned to the treatment group and the control group, 25 in each group. Patients in the control group were treated with gemcitabine and concurrent 3D-CRT, while those in the treatment group were also treated with intravenous injection of KI (at 100 mL/d) for 21 successive days, 28 days as one cycle, two cycles with one week interval. The short-term curative effect, the survival time, the improvement of symptoms, the tumor markers, and adverse reactions were respectively observed for two years.</p><p><b>RESULTS</b>The short-term curative effective rate (CR + PR) was 52.17% (12/23), and the disease control rate (CR + PR + SD) was 95.65% (22/23) in the treatment group. The short-term curative effective rate (CR + PR) was 41.67% (10/24), and the disease control rate (CR + PR + SD) was 87.50% (21/24) in the control group. There was no statistical difference between the two groups (P > 0.05). The 2-year survival rate was 34.78% (8/23) in the treatment group, better than that in the control group (25.00%, 6/24). The median survival time was 17.2 months in the treatment group and 12.4 months in the control group with statistical difference (P < 0.05). The response rate of pain relief and weight gain were 75.00% and 82.61% in the treatment group respectively, and they were 50.00% and 54.67% in the control group respectively, showing statistical difference between the two groups (P < 0.05). After treatment, the levels of CA19-9 (U/mL) and CEA (ng/mL) were respectively reduced to 118. 00 +/- 78.89 and 7.41 +/- 2.37 respectively in the treatment group, showing statistical difference when compared with those of the control group (being 216.00 +/- 153.23 and 12.25 +/- 7.53 respectively, P < 0.05).</p><p><b>CONCLUSION</b>The concurrent chemoradiotherapy com- bined with KI for locally advanced pancreatic carcinoma patients obtained better results.</p>


Assuntos
Adolescente , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Terapia Combinada , Desoxicitidina , Usos Terapêuticos , Medicamentos de Ervas Chinesas , Usos Terapêuticos , Neoplasias Pancreáticas , Patologia , Terapêutica , Fitoterapia , Radioterapia Conformacional
2.
Chinese Journal of Integrated Traditional and Western Medicine ; (12): 1250-1252, 2010.
Artigo em Chinês | WPRIM | ID: wpr-327460

RESUMO

<p><b>OBJECTIVE</b>To investigate the myocardial protective effect of Rhodiola on patients who received epidoxorubicin (EPI) treatment.</p><p><b>METHODS</b>Forty-two patients with myocardial damage who received 3 courses of EPI-contained chemotherapy were randomly and equally assigned to two groups, the Rhodiola treated group and the control group. After 1-month treatment, the changes in serum troponin I (cTnI) level, cardiac integral backscatter (IBS), and left ventricle ejective fraction (LVEF) in patients were observed and compared between groups.</p><p><b>RESULTS</b>Levels of cTnI in the treated group and control group were (0.54 +/- 0.05) mg/L and (0.98 +/- 0.03) mg/L respectively, IBS were 55.23 +/- 5.72 scores and 61.23 +/- 5.96 scores, and LVEF (%) were 68 +/- 3 and 57 +/- 2 respectively, all showed significant differences between groups (P<0.05).</p><p><b>CONCLUSION</b>Rhodiola can improve cardiac function, and suppress the increase of serum cTnI level and IBS in patients who received EPI treatment.</p>


Assuntos
Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Protocolos de Quimioterapia Combinada Antineoplásica , Usos Terapêuticos , Neoplasias da Mama , Tratamento Farmacológico , Cirurgia Geral , Medicamentos de Ervas Chinesas , Usos Terapêuticos , Epirubicina , Miocárdio , Patologia , Fitoterapia , Período Pós-Operatório , Substâncias Protetoras , Usos Terapêuticos , Rhodiola , Química , Neoplasias Gástricas , Tratamento Farmacológico , Cirurgia Geral , Volume Sistólico , Troponina I , Sangue
3.
Chinese journal of integrative medicine ; (12): 5-10, 2005.
Artigo em Inglês | WPRIM | ID: wpr-336513

RESUMO

<p><b>OBJECTIVE</b>To evaluate the clinical efficacy of Ganxian recipe (GXR) and lamivudine (LVD) in a two-year treatment of chronic hepatitis B (CHB).</p><p><b>METHODS</b>One hundred and twenty patients with CHB were randomly divided into the combinedly treated group (combined group) of 40 CHB patients who were treated with GXR combined with LVD. Another 40 CHB patients were treated with LVD alone (WM group), and still another 40 CHB patients were treated with GXR alone (TCM group). All these cases were randomly controlled and observed for two years.</p><p><b>RESULTS</b>Comprehensive efficacy: Total effective rate of the combined group (complete response and partial response) was 92.5%, while that of the WM group was 67.5% and TCM group 57.5%, respectively, with the difference between them was significant (P < 0.01); after treatment, the hepatic functions (AST, ALT, SB) of the three groups were all reduced, and the reduction in the combined group was particularly significant in comparison with the WM group or TCM group, P < 0.05 or P < 0.01 respectively, suggesting that the effect in the combined group was better than that in the other two groups; the rate of tyrosine-methionine-aspartate-aspartate (YMDD) virus mutation: it was 7.5% in the combined group, 40.0% in the WM group, and 5.0% in the TCM group; liver fibrosis improvement parameter: after treatment, the results in the combined group got better than those in the other two groups.</p><p><b>CONCLUSION</b>GXR could inhibit the appearance of YMDD after long-term application of LVD, and combined use has marked synergism.</p>


Assuntos
Adolescente , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Frequência do Gene , Genes Virais , Anticorpos Anti-Hepatite B , Sangue , Antígenos E da Hepatite B , Sangue , Alergia e Imunologia , Vírus da Hepatite B , Genética , Hepatite B Crônica , Terapêutica , Virologia , Lamivudina , Usos Terapêuticos , Fígado , Cirrose Hepática , Patologia , Virologia , Medicina Tradicional Chinesa , Métodos , Mutação , Fitoterapia , Preparações de Plantas , Usos Terapêuticos , Inibidores da Transcriptase Reversa , Usos Terapêuticos , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA